NP has done a fine job representing CYDY with the FDA. That is one area where he deserves a lot of credit. Moving forward the company needs to do a better job of communicating its financial plans to shareholders so they can better understand from where capital will be sourced and at what price points. I think the company does a good job being transparent as far as the science and clinical studies, but has not matched that candor when it comes to capital planning and its associated challenges. Because CYDY is a "retail investor owned" company the IR function must improve its personal engagement beyond what is needed by more institution owned and dominated public companies.